Relief Therapeutics to Acquire FirstString, Move Sarcoidosis and Diabetes Therapies into Phase 3 Trials
Relief Therapeutics, readying for a pivotal clinical trial of a sarcoidosis treatment, announced that it is acquiring FirstString Research in an all-stock transaction that will add an advanced clinical stage product, Granexin, a potential treatment for diabetic foot ulcers and venous leg ulcers, to its drug portfolio. Relief will  also acquire FirstString’s pipeline…